

Cat No. 72-C33

BIBW-2992


5 mg



For research purposes only

BIBW-2992 is a irreversible and dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) kinases. The potency of BIBW-2992 on the EGFR and HER2 kinases revealed IC_{50} values of 0.5 nM and 14 nM, respectively. BIBW-2992 is highly selective for these kinases and no additional inhibition of other kinases has been observed. BIBW-2992 has also been shown to suppress EGF-induced EGFR phosphorylation and cellular proliferation in various cell lines.

TECHNICAL INFORMATION



Other Names: Afatinib

Chemical Formula: $C_{24}H_{25}ClFN_5O_3$

CAS Number: 850140-72-6

Molecular Weight: 485.94

Purity: >98%

Appearance: a crystalline solid

Solubility: DMSO

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in DMSO at 200 mg/ml. Soluble in ethanol at 25mg/ml. If precipitate is observed, vortex for 5 minutes. For most cells, the maximum tolerance to DMSO is less than 0.5%.

REFERENCES

1. Li et al. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. *Oncogene*. 27(34):4702-11.
2. Takezawa et al. (2010) Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. *Mol Cancer Ther*. 9(6):1647-56.
3. Minkovsky et al. (2008) BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. *Curr Opin Investig Drugs*. 9(12): 1336-46.